Compare MBIN & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | NKTR |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | 735 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | N/A | 1996 |
| Metric | MBIN | NKTR |
|---|---|---|
| Price | $54.87 | $69.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $43.67 | ★ $146.67 |
| AVG Volume (30 Days) | 143.9K | ★ 780.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $31.76 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $29.20 | $21.60 |
| 52 Week High | $56.87 | $109.00 |
| Indicator | MBIN | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 73.49 | 53.68 |
| Support Level | $45.39 | $64.28 |
| Resistance Level | N/A | $76.78 |
| Average True Range (ATR) | 1.76 | 3.30 |
| MACD | 0.79 | 0.12 |
| Stochastic Oscillator | 89.97 | 62.78 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.